Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.
Euro Surveill. 2017 Feb 09;22(6):
Authors: Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M
Abstract
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network (SPSN) assessed interim 2016/17 influenza vaccine effectiveness (VE) against dominant influenza A(H3N2) viruses considered antigenically matched to the clade 3C.2a vaccine strain. Sequence analysis revealed substantial heterogeneity in emerging 3C.2a1 variants by province and over time. Adjusted VE was 42% (95% confidence interval: 18-59%) overall, with variation by province. Interim virological and VE findings reported here warrant further investigation to inform potential vaccine reformulation.
PMID: 28205503 [PubMed - in process]

Source: Euro Surveill - February 8, 2017 Category: Infectious Diseases Authors: Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M Tags: Euro Surveill Source Type: research